Autism Spectrum Disorder and Cannabis

Autism Spectrum Disorder: Clinical Challenges

• Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by differences in social communication, sensory processing and behaviour; UK prevalence is estimated at 1.1%.
• There is no approved pharmacological treatment for the core features of ASD; medications are used only to manage associated conditions such as anxiety, hyperactivity and sleep disorders.
• The high prevalence of co-occurring anxiety (40–60%), sleep disturbance (80%) and behavioural dysregulation in ASD patients creates significant unmet pharmacological need.
• Parents and carers of autistic children have been among the most vocal advocates for medical cannabis access in the UK, particularly for severe behavioural and epilepsy comorbidities.

The significant pharmacological gaps in ASD treatment, particularly for anxiety and sleep, have driven families and adult patients to investigate medical cannabis as a potential adjunct.

Cannabis and the Endocannabinoid System in ASD

• Emerging research suggests that the endocannabinoid system may be dysregulated in ASD; altered anandamide levels and CB1 receptor expression have been reported in affected individuals.
• CBD’s broad modulatory effects on serotonin, GABA and glutamate systems — all implicated in ASD neurobiology — provide a mechanistic rationale for its therapeutic investigation.
• Oxytocin release, which is reduced in ASD and associated with social communication difficulties, may be enhanced by endocannabinoid system modulation.
• For comorbid epilepsy in ASD, Epidyolex (pharmaceutical CBD) has received MHRA approval, providing a licensed treatment option within the ASD population.

The convergence of endocannabinoid system dysregulation and the specific pharmacological gaps in ASD management makes cannabis medicine an area of genuine scientific interest.

Clinical Evidence in ASD Populations

• A 2019 Israeli prospective study of 188 ASD patients treated with cannabis oil reported significant improvements in behavioural problems, anxiety and communication at six months.
• A 2020 randomised controlled trial of cannabidivarin (CBDV) in adults with ASD by King’s College London found improvements in social communication measures compared to placebo.
• UK paediatric neurologists have prescribed Epidyolex for ASD-associated epilepsy under the same MHRA licence that applies to Dravet syndrome and Lennox-Gastaut syndrome.
• Adult ASD patients treated with cannabis for comorbid anxiety and sleep disorders in UK clinics report improvements in these secondary outcomes, with variable effects on core ASD features.

The evidence base for cannabis in ASD is growing, driven partly by Israeli and North American research; UK clinicians are increasingly engaged with the science even as prescribing remains cautious.

Access and Prescribing for ASD Patients in the UK

• For paediatric ASD with comorbid epilepsy, Epidyolex is the appropriate licensed product; prescribing is through NHS paediatric neurology and specific MHRA criteria apply.
• Adult ASD patients with comorbid anxiety, insomnia or PTSD may be considered for medical cannabis prescribing by specialist UK clinics for these secondary indications.
• ASD-specific cannabis prescribing requires careful assessment of communication needs; clinics experienced in neurodevelopmental conditions are preferable for this population.
• Families pursuing medical cannabis for ASD children outside the licensed Epidyolex pathway should be aware of the legal and safety complexities; specialist legal and medical advice is essential.

ASD patients and their families benefit most from engaging with specialist cannabis clinics that have experience with neurodevelopmental conditions and can navigate the nuanced prescribing landscape effectively.